MEI Pharma inc – MEIP Has 3 upcoming catalyst in 2Q 2018:
Pracinostat in combination with Vidaza
High-risk Myelodysplastic Syndrome (MDS)
Phase 2 commencement of dosing announced June 14, 2017 – data from first stage due 2Q 2018.
Relapsed/refractory Follicular Lymphoma/Chronic Lymphocytic Leukemia (CLL)
Phase 1b data to be presented 2Q 2018.
HER2-negative Breast Cancer
Phase 1 data due 2Q 2018.